Monday's Health Winners & Losers - TheStreet

Monday's Health Winners & Losers

Dendreon continues to advance, after Friday's good news from the FDA on its prostate drug.
Author:
Publish date:

Updated from 12:58 p.m. EDT

Dendreon

(DNDN)

was one of Monday's best performers. On Friday, the Food and Drug Administration said the company's prostate cancer vaccine treatment, Provenge, was safe and effective in treating prostate cancer. A final decision from the FDA is expected on May 15. Shares of Dendreon, which soared 147% on Friday, closed up $1.37, or 10.6%, to $14.30.

Novavax

(NVAX) - Get Report

jumped 17.8% after the company said its vaccine prevention for H9N2, another strain of the avian flu virus, was effective when tested on animals. Shares of Novavax gained 46 cents to $3.05.

Shares of

Cephalon

(CEPH)

were also higher after Jefferies upgraded the stock to buy from hold. The firm also upped Cephalon's stock price target to $88 from $69. The stock climbed $4.75, or 6.7%, to $75.96.

On the other hand,

Bruker BioSciences

(BRKR) - Get Report

was losing ground after Bear Stearns lowered its rating on the company to underperform from peer perform. Shares of Bruker were recently down 26 cents, or 2.5%, to $10.26.

Among other health care winners,

Celgene

(CELG) - Get Report

added 2.6% to $53.80.

MedcoHealth Solutions

(MHS)

was gaining 1.8% to $73.84.

Merck

(MRK) - Get Report

was higher by 1.9% at $45.01.

Among decliners,

CV Therapeutics

(CVTX)

shed 4.5% to $7.62.

MedImmune

(MEDI)

was off 2.2% to $35.60, and

Schering-Plough

(SGP)

was lower by 0.4% at $25.42.